Education
About Us
Working with TipRanks
Follow Us
Femasys, Inc. (FEMY)
NASDAQ:FEMY
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$0.31 - $1.80
Previous CloseN/A
Volume25.00K
Average Volume (3M)1.24M
Market Cap
$35.39M
Enterprise Value$18.31M
Total Cash (Recent Filing)$4.57M
Total Debt (Recent Filing)$8.43M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Mar 26, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding59,501,854
10 Day Avg. Volume847,432
30 Day Avg. Volume1,238,307
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)10.63
Price to Sales (P/S)15.04
P/FCF Ratio-1.21
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue8.88
Enterprise Value/Gross Profit20.96
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$4.75Price Target Upside550.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Global ExpansionFemasys continues to advance the global expansion of its permanent birth control product, FemBloc, securing regulatory approvals in the UK.
Revenue GrowthFemasys reported results with $0.7M in revenue primarily from sales of FemBloc and commercial products, up 78%.
Strategic PartnershipsFemasys has secured a significant strategic partnership with Kebomed to commercialize its FemBloc across France and the Benelux region, marking a major step in its European growth strategy.
Bears Say
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $0.31 and its highest was $1.80 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $35.39M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 71 days.
How were Femasys, Inc.’s earnings last quarter?
Femasys, Inc. released its earnings results on Nov 14, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.115 by $0.015.
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Undervalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate is -0.09.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 59,501,854 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Femasys, Inc. reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.115. Following the earnings report the stock price went up 8.596%.
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Femasys Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.75 (550.68% Upside)
$4.75 (550.68% Upside)
Blogger Sentiment
Bullish
FEMY Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.8%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.00%
12-Months-Change
Fundamentals
Return on Equity
-376.23%
Trailing 12-Months
Asset Growth
4.52%
Trailing 12-Months
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
FEMY Stock 12 Month Forecast
Average Price Target
$4.75
▲(550.68% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
3.11% Insiders
1.81% Mutual Funds
3.80% Other Institutional Investors
89.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---